The China National Medical Products Administration approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Dark Blue Therapeutics was acquired by Amgen.
Niowave Inc. and AstraZeneca are expanding their existing supply agreement to a 10-year commitment to deliver actinium-225, following AstraZeneca’s decision to exercise its option to increase capacity.
Kallisio has collaborated with Stanford Health Care to support the clinical implementation of its FDA-cleared Stentra system for use in head-and-neck cancer radiation therapy.
SOPHiA GENETICS and The University of Texas MD Anderson Cancer Center have entered into a collaboration to accelerate data-driven cancer care through new tools that can accurately analyze, interpret, and translate diagnostic results into clinical practice.
The National Cancer Institute approved the following clinical research studies last month.
As trust in scientific and regulatory institutions frays and the meaning of “gold standard science” is increasingly contested, cancer research faces a credibility test of its own.
Earlier this month, NCI released a new Cancer Center Support Grant Notice of Funding Opportunity. Except for the elimination of the Plan to Enhance Diversity component and lengthening of the Shared Resource write-ups from three to six pages, the guidelines are essentially unchanged.
New Year’s Eve approaches, and with it, a chance to turn a new leaf with renewed energy, to reflect on—or perhaps, in the case of 2025, bemoan—the events of the year, and, most importantly, to celebrate.
Angelo de Claro was named acting director of the FDA Oncology Center of Excellence, following Richard Pazdur’s departure from that position—and the agency (The Cancer Letter, Dec. 5, 2025).
